Browsing Tag
Novo Nordisk
97 posts
Mitsui’s Kassø e-methanol lands OMV as RFNBO offtaker, unlocking EU land fuel demand
Mitsui and European Energy added OMV as RFNBO offtaker for Kassø's e-methanol; four verticals now anchor a plant whose value lies in template, not tonnage.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Why MedPal AI (AIM: MPAL) is betting on today’s oral Wegovy launch
Oral Wegovy launches in the UK today. MedPal AI just raised £5m and bought a care-home tech firm to try to ride the wave from day one.
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.